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INTERIM FINDINGS ON THE EVALUATION OF SPLIT DRUG
REGIMENS FOR PULMONARY TUBERCULOSIS - A
RANDOMIZED CONTROLLED CLINICAL TRIAL*
TUBERCULOSIS RESEARCH CENTRE, MADRAS
Summary: A randomized controlled clinical
t r i a l  o f  t h ree  f u l l y  o ra l  sho r t  cou r se
chemotherapy regimens of 6 month duration
is being conducted to evaluate split-dose
double drug combinations for the treatment
of sputum positive pulmonary tuberculosis.
Split I  and Split I I  regimens consist of
Rifa mpicin and Ethambutol on one day and
lsoniazid and Pyrazinamide on the next day,
each combination given thrice a week during
the initial intensive phase of 2 or 3 months,
respectively, followed by Rifampicin and
Isoniazid given twice a week during the
continuation phase for the next 4 and 3
months; respectively. The control regimen
consists of all the four drugs, Rifampicin,
Isoniazid, Pyrazinamide and Ethambutol,
given together in a single dose thrice a week
during the intensive phase of first 2 months,
and Rifampicin and Isoniazid twice a week
during the continuation phase of next 4
m o n t h s .  D r u g s  w e r e  g i v e n  u n d e r  f u l l
supervision during the entire chemotherapy
period of 6 months. The findings upto the
end of chemotherapy for 750 patients suggest
that the response is similar in split and
contro l  reg imens among pat ients  wi th
sensitive organisms and those with resistance
to Isoniazid alone. Among patients with
organisms resistant to both Isoniazid and
Rifampicin, almost all had an unfavourable
response. Adverse reactions were low and
similar in both split and control regimens.
Introduction
Several highly effective short course
chemotherapy regimens have been evolved for
the treatment of sputum, positive pulmonary
tuberculosis. In most of these regimens, four
drugs, viz, Rifampicin(R), Isoniazid(H), 
Pyrazinamide(Z) and Streptomycin(S) or
Ethambutol(E) are given together in a single dose
either daily or intermittently in the initial phase.
The bulk of the drugs to be consumed in a single
dose is, therefore, large and may affect patient
compliance. Further, the incidence of adverse
reactions such as arthralgia and jaundice is higher
with daily regimens.
Hence, a study is being conducted wherein
the four drugs are split into two 2-drug
combinations, each combination given on alternate
days, thus making each combination intermittent.
The advantage of the split regimens is that the
bulk of the drugs in a tingle dose is less and
adverse reactions are expected to be low. These
two factors together will presumably help in
improving patient compliance.
Study Subjects
The patients were residents of either Madras
or Madurai, and had come to the out-patients
chest clinics because of symptoms. Patients were
eligible for inclusion in the study irrespective of
previous chemotherapy, if they were aged 12
years or more, had at least 2 sputum cultures
positive for M. tuberculosis, even though admission
to the study was based on smear positivity, and
were willing to attend the centre for supervised
chemotherapy for a period of 6 months. Patients
with diabetes, hypertension. bleeding diathesis
and extra pulmonary tuberculosis were not eligible
for the study.
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Regimens
Patients were randomly allocated, stratified
on the basis of duration of previous chemotherapy
and degree of sputum positivity, to one of the
following three fully supervised regimens of 6
months’ duration.
In the first regimen, 2RE3HZ3(alt)/4RH2
(split I), during the initial phase, Rifampicin and
Ethambutol were given on one day and Isoniazid
and Pyrazinamide on the next day, thrice a week
for 2 months followed by Rifampicin and Isoniazid
twice a week for the next 4 months. The second
regimen,3RE3HZ3 (alt)/3RH2 (split II), was
similar to regimen 1, but the initial phase was
for 3 months, followed by 3 months in the
continuation phase. The third regimen (2REHZ3/
4RH2) was the control regimen where all four
drugs were given together in a single dose thrice
a week for 2 months followed by Rifampicin and
Isoniazid twice a week for next 4 months. The
dosages were same for all the three regimens in
both the phases. For patients weighing 40 kg or
less, rifampicin 450 mg, Ethambutol 1000 mg
and Pyrazinamide 1.5 g were given. For patients
weighing more than 40 kg, the dosages were 600
mg, 1200 mg and 2 g, respectively. Isoniazid was
given in a flat dose of 600 mg, irrespective of
body weight.
population consisted of 750 patients of whom 124
were excluded for various reasons like negative
culture on admission, early death, death due to
non-tuberculous causes and for having missed
25% or more of chemotherapy. There remained
a total of 626 patients in the analysis. Of these,
80% had organisms sensitive to Isoniazid and
Rifampicin, 16% of patients had resistance to
Isoniazid alone, 0.3% had resistance to Rifampicin
alo e and 3% of patients had resistance to both
Ison azid and Rifampicin (Table 1).
During chemotherapy, 3 sputum specimens
from each patient were examined by culture for
M. tuberculosis every month. The proportion of
patients with negative culture at first month was
29% and 30% in split I and II regimens,
respectively and 28% in the control regimen. By
second month, it had gone up to 80-83%. From
3rd to 6th month it was 95 - 99%. Thus the speed
of sputum conversion was similar in all the
regimens (Table 2).
Results
P oportion of patients who received more
than 80% of their prescribed chemotherapy was
82% and 85% in split I and II regimens,
r spectively and 82% in the control regimen.
Even though patients had to attend daily for the
nitial 2 to 3 months in the split regimens, the
drug regularity was similar to that of control
regimen where they had lo attend thrice a week
during this period. (Table 3).
The findings of the interim analysis uptoA favourable bacteriological response at the
the end of chemotherapy are presented here. Thend of chemotherapy was defined as all cultures
Table 1. Study population
Total patients
Exclusions
Total in analysis
Sensitive to H and R
Resistant to H alone
Resistant IO R alone
Resistant to H and R
2RE3HZ3(alt)/ 3RE3HZ3(alt)/
4RHZ 3RH2
(Split I) (Split II)
251 250
43 38
208 212
173 169
27 36
1 1
7 6
2REHZ3/ Total
4RH2
(Control)
249 750
43 124
206 626
162 504 (80%)
38 101 (16%)
0 2 (0.3%)
6 19 (3%)
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Table 2. Culture negativity (%) during treatment among patients with initial drug sensitive
organisms
Months after start
of treatment
1
2
3
4
5
6
2RE3HZ3(alt)/ 3RE3HZ3(alt)/ 2REHZ/
4RH2 3RH2 4RH2
(Split I) (Split II) (Control)
28 30 29
80 83 82
97 96 96
97 99 98
95 98 96
97 95 98
Range of 171 - 173 168 - 169 161 - 162
Patients
Table 3. Percentage of chemotherapy received during phases I & II
T r e a t m e n t
received(%)
2RE3HZ3(alt)/4RH2
(Split I)
Number of patients
3RE3HZ3(alt)/3RH2
(Split II)
2REHZ3/4RH2
(Control)
> 80 195(82)* 204(85) 200(82)
50 - 79 28(12) 24(10) 22(9)
< 50 1(<1) 0(0) 1(<1)
Missed continuously 14(6) 13(5) 20(8)
for >1 month
Total
* Percentages in parenthesis
238 241 243
Table 4. Response at the end of chemotherapy among patients with initial drug sensitive organisms
Response Number of patients
Favourable
Doubtful
Unfavourable
Total
* Percentages in parenthesis
2RH3ZH3(alt)/
4RH2           
(Split I)
163(94)*
6(3)
4(2)
173
3RE3HZ3(alt)/
3RH2
(Split II)
158(93)
9(5)
2(1)
169
2REHZ3/
4RH2
(Control)
152(94)
10(6)
0(0)
162
negative in the last two months of chemotherapy.
An unfavourable bacteriological response was
defined as 2 or more cultures being positive in
the last two months of treatment including one
culture in the last month and a least one culture
growing 20 colonies or more. In addition, patients
who had a change of treatment for persistent
culture positivity, or radiographic or clinical
deterioration and those who died of tuberculosis
were also classified as having had an unfavourable
response. Those who did not fit into these criteria
were classified as having doubtful response.
A  the end of chemotherapy, among patients
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with drug sensitive organisms, a favourable
response was obtained in 94% and 93% in split
I and II regimens, respectively and 94% in the
control regimen. It can be observed that the
response at the end of treatment is not very much
affected by splitting the drugs. All those with
doubtful response converted by 7th month without
additional chemotherapy. Only 2% and 1% of
patients, respectively in the split I and II regimens
had unfavourable response (Table 4).
Among those with organisms resistant to
Isoniazid alone, favourable response was seen in
78% and 81%, respectively in split I and II
regimens and 73% in the control regimen, while
unfavourable response was seen in 19%, 14% and
21% respectively in the three regimens. Out of
these patients with unfavourable response, one
died and all the others had change of treatment
for persistent culture positivity (Table 5).
There were 19 patients with organisms
resistant to both Isoniazid and Rifampicin. Except
one, all the others had an unfavourable response.
Two patients who had resistance to Rifampicin
lone had a favourable response.
Adverse reactions
Adverse reactions encountered during
chemotherapy were mainly gastro-intestinal
symptoms, arthralgia, hepatitis and cutaneous
reactions. Proportions of patients reporting with
any of these complaints were 11%, 18% and
17%, respectively, in the 3 regimens. The difference
between split regimens and control regimen was
not statistically significant (Table 6). Majority of
the adverse reactions were managed
symptomatically. Modification of chemotherapy
had to be done only in 14 patients. One patient
(split I) developed hypersensitivity reaction during
the third week of treatment in the form of severe
burning all over with hot flushes, when he was
receiving Isoniazid and Pyrazinamide. Attempts
Table 5. Response at the end of chemotherapy among patients with initial H resistant organ
2RE3HZ3(alt)/4RH2 3RE3HZ3(alt)/3RH2
(Split I) (Split II)
No. % No. %
21 78 29 81
1 4 2 6
5 19 5 14
27 36
Table 6. Adverse reactions
Regimen Total Patients with complaints
No. of
patients Any Gastro- Arthr- Cutan- Giddi- Hcpa-  Others
intestinal algia eous ness titis
2RE3HZ3 (alt)/
4RH2
(Split I) 243 27(11)* 9 7 7 3 2 1
3RE3HZ3(alt)
3RH2
(Split II) 244 43(18) 13 19 6 4 3
2REHZ3/4RH2
(Control) 244 41(17) 20 7 9 6 1 4
Percentages in parenthesis
* Includes “flu” syndrome, hypersensitivity reaction and peripheral neuropathy
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for desensitization for both Isoniazid and
Pyrazinamide failed and the drugs were terminated.
Rifampicin was terminated in three patients. One
patient (control) developed itching with purpuric
rashes during the third week of treatment, second
patient (control) had ‘flu’ syndrome from the
second dose of treatment (this patient had received
Rifampicin outside before admission to the study)
and the third patient (split II) had fever and
breathlessness after receiving Rifampicin and
Ethambutol  combinat ion,  developed
hypersensitivity reaction while under observation
in the clinic after receiving Rifampicin. Nine
pati ents had interruption of drugs, seven for
jaundice (2 split I, 4 split II, 1 control). Of these,
five patients developed jaundice during the initial
intensive phase. Rifampicin and Isoniazid (and
Pyrazinamide in the initial phase) were withheld
temporarily and reintroduced after subsidence of
jaundice without any problem. The other two
patients had interruption of the offending drug
for severe glossitis in one and itching in the other.
For these two patients also, drugs were reintroduced
without any problem. One patient (control) had
severe gastrointestinal problem and the dosage of
the drugs had to be reduced.
Discussion
Several studies have shown that short course
regimens using the four drugs viz, Rifampicin,
Iso niazid, Pyrazinamide and Streptomycin or
Ethambutol during the intensive phase are effective
in the treatment of sputum positive pulmonary
tuberculosis1-3. However, in these regimens patients
find it difficult  to consume the drugs given either
daily or intermittently because of the bulk. An
in vitro study done at our centre has demonstrated
that splitting the 4 drugs REHZ into 2 split drug
combinations of RE and HZ may not affect the
bactericidal action of the regimens4. Further. it
has already been reported from experimental
murine tuberculosis that split dose alternating
regimens are as effective as giving all the 4 drugs
together5. Thus, it was assumed that anti-
tuberculosis drugs given in split combination
would be effective in human beings as well.
Hence, the Tuberculosis Research Centre
conducted a controlled clinical trial in sputum
positive pulmonary tuberculosis where the 3 drug
combination was split into two 2-drug
combinations, combination given on alternate
each days, thus making each combination
intermittent.
This study, as far as we are aware, is
uniqu  because split drug combinations were
used in a controlled clinical trial in sputum
positive pulmonary tuberculosis patients for
the first time.
The results indicate that in patients with
initially drug sensitive organisms, the split
regimens have ahigh sterilizing activity,
producing sputum conversion in 80 to 83% by
2 months, which is similar to that in the
control regimen. This result compares well
with the findings of 80 - 87% conversion in
East African patients treated with short course
chemotherapy6-7. At the end of chemotherapy,
a favourable response (all cultures negative in
the last two months of chemotherapy) was
bserved in 93 - 94% in split regimens which
is again similar to that in the control regimen
(Table 4). This finding is in conformity with
the observations from in vitro studies, animal
experiments and in vivo studies4,5,8,9.
Among patients with bacilli resistant to ‘H’
alone favourable response was observed in 78%
and 81%,respectively, in split I and II regimens
which is similar to the 74% in control regimen,
wher as in patients with organisms resistant to
both Isoniazid and Rifampicin almost all had an
u favourable response.
Adverse reactions were generally low and
similar in both split and control regimens. Patients
were not questioned about symptoms of drug
toxicity, but every spontaneous complaint was
recorded after careful questioning by a physican.
Main adverse reactions encountered were gastro-
intestinal symptoms, arthralgia, hepatitis and
cutaneous reactions. Proportions of patients with
any of these complaints were 11% and 18% in
split regimens and 17% in the control regimen.
This is much lower than that observed at the
centre in earlier SCC regimens with daily treatment
i  the initial intensive phase1. Modification of
che otherapy (termination, interruption, reduction)
we e necessary in only 14 cases.
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Thus. there does not appear to be any
difference either in the efficacy of regimens or
toxicity when drugs are administered as split
regimens (alternately) compared to giving all the
4 drugs together. All patients are being followed-
up to assess the efficacy of the double drug
combination regimens with long term follow up
for possible relapses. It may be presumed that
the relapses would be minimal since the culture
negativity rates at the end of 2 months of
intensive chemotherapy are of the order of 80
to 83%8.
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